EAM
BIOT

Exos Asset Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Exos Asset Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$242K – 810
2021
Q2 		$242K Hold
25,000
– – 0.13% 251
2021
Q1 		$242K Buy
+25,000
New +$242K 0.19% 188

Other funds holding BIOT

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Exos Asset Management's BIOT Position: Q3 2021 in Review

Exos Asset Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2021, closing a stake of 25,000 shares — an estimated $242K sold.

Exos Asset Management first reported a position in BIOT in Q1 2021 and held it in 2 quarters. The position peaked at $242K in Q2 2021. 58 funds tracked by Wall St. Rank hold BIOT as of Q3 2021.

  • Exos Asset Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • Exos Asset Management sold 25,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2021, an estimated $242K.
  • Exos Asset Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 2 quarters.
  • Exos Asset Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $242K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.